Compare MGM Resorts International (MGM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Novartis AG — how do they compare? MGM Resorts International trades at $29.74 (market cap $7.55B), while Novartis AG trades at $143.32 (market cap $268.57B). The key difference: Novartis AG is far larger — about 35.6× MGM Resorts International's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Novartis AG for 82 Days on average.
| MGM | NVS | |
|---|---|---|
Market Cap | $7.55B | $268.57B |
Volume | 5,342,346 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $168.62 |
52-Week Low | $30.00 | $121.80 |
Typical Hold Time | 91 Days | 82 Days |
Enterprise Value | $34.85B | $309.89B |
Dividend Yield | 0.03% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day and facing bearish technical momentum despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $17.54B in 2025 but declining net margins to 1.17%. Recent market sentiment has been negatively impacted by the collapse of Barry Diller's $48.30 per share acquisition offer, though MGM is now exploring a potential bid for Diller's People Inc. Analyst consensus remains bullish with a $48.75 price target representing significant upside potential.
The stock presents a compelling value opportunity with attractive valuation metrics (P/E 18.19, P/S 0.45) and strong analyst support, but faces near-term headwinds from deal uncertainty and bearish technical signals. Key risks include execution challenges in potential M&A activity and ongoing margin pressure in the competitive gaming sector.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
